121 related articles for article (PubMed ID: 37748860)
1. Mosaic
Schwartz M; Ibadioune S; Chansavang A; Vacher S; Caputo SM; Delhomelle H; Wong J; Abidallah K; Moncoutier V; Becette V; Popova T; Suybeng V; De Pauw A; Stern MH; Colas C; Mouret-Fourme E; Stoppa-Lyonnet D; Golmard L; Bieche I; Masliah-Planchon J
J Med Genet; 2024 Feb; 61(3):284-288. PubMed ID: 37748860
[TBL] [Abstract][Full Text] [Related]
2. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG
Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112
[TBL] [Abstract][Full Text] [Related]
3. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
4. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
6. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract][Full Text] [Related]
7. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
Ghimenti C; Sensi E; Presciuttini S; Brunetti IM; Conte P; Bevilacqua G; Caligo MA
Genes Chromosomes Cancer; 2002 Mar; 33(3):235-42. PubMed ID: 11807980
[TBL] [Abstract][Full Text] [Related]
8. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
[TBL] [Abstract][Full Text] [Related]
9. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
10. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
[TBL] [Abstract][Full Text] [Related]
11. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
13. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
Clague J; Wilhoite G; Adamson A; Bailis A; Weitzel JN; Neuhausen SL
PLoS One; 2011; 6(9):e25632. PubMed ID: 21980511
[TBL] [Abstract][Full Text] [Related]
14. Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.
Scott CM; Joo JE; O'Callaghan N; Buchanan DD; Clendenning M; Giles GG; Hopper JL; Wong EM; Southey MC
PLoS One; 2016; 11(11):e0165436. PubMed ID: 27902704
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
[TBL] [Abstract][Full Text] [Related]
16. Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
Cao WM; Gao Y; Yang HJ; Xie SN; Ding XW; Pan ZW; Ye WW; Wang XJ
BMC Cancer; 2016 Feb; 16():64. PubMed ID: 26852015
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
[TBL] [Abstract][Full Text] [Related]
18. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.
Hansmann T; Pliushch G; Leubner M; Kroll P; Endt D; Gehrig A; Preisler-Adams S; Wieacker P; Haaf T
Hum Mol Genet; 2012 Nov; 21(21):4669-79. PubMed ID: 22843497
[TBL] [Abstract][Full Text] [Related]
19. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
Cherbal F; Bakour R; Adane S; Boualga K; Benais-Pont G; Maillet P
Dis Markers; 2010; 28(6):377-84. PubMed ID: 20683152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
